Salmen Anke, Hoepner Robert, Fleischer Vinzenz, Heldt Milena, Gisevius Barbara, Motte Jeremias, Ruprecht Klemens, Schneider Ruth, Fisse Anna Lena, Grüter Thomas, Lukas Carsten, Berthele Achim, Giglhuber Katrin, Flaskamp Martina, Mühlau Mark, Kirschke Jan, Bittner Stefan, Groppa Sergiu, Lüssi Felix, Bayas Antonios, Meuth Sven, Heesen Cristoph, Trebst Corinna, Wildemann Brigitte, Then Bergh Florian, Antony Gisela, Kümpfel Tania, Paul Friedemann, Nischwitz Sandra, Tumani Hayrettin, Zettl Uwe, Hemmer Bernhard, Wiendl Heinz, Zipp Frauke, Gold Ralf
Department of Neurology, St. Josef-Hospital Bochum, Ruhr-University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany.
Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
Ther Adv Neurol Disord. 2023 Sep 8;16:17562864231197309. doi: 10.1177/17562864231197309. eCollection 2023.
BACKGROUND: Depression has a major impact on the disease burden of multiple sclerosis (MS). Analyses of overlapping MS and depression risk factors [smoking, vitamin D (25-OH-VD) and Epstein-Barr virus (EBV) infection] and sex, age, disease characteristics and neuroimaging features associated with depressive symptoms in early MS are scarce. OBJECTIVES: To assess an association of MS risk factors with depressive symptoms within the German NationMS cohort. DESIGN: Cross-sectional analysis within a multicenter observational study. METHODS: Baseline data of = 781 adults with newly diagnosed clinically isolated syndrome or relapsing-remitting MS qualified for analysis. Global and region-specific magnetic resonance imaging (MRI)-volumetry parameters were available for = 327 patients. Association of demographic factors, MS characteristics and risk factors [sex, age, smoking, disease course, presence of current relapse, expanded disability status scale (EDSS) score, fatigue (fatigue scale motor cognition), 25-OH-VD serum concentration, EBV nuclear antigen-1 IgG (EBNA1-IgG) serum levels] and depressive symptoms (Beck Depression Inventory-II, BDI-II) was tested as a primary outcome by multivariable linear regression. Non-parametric correlation and group comparison were performed for associations of MRI parameters and depressive symptoms. RESULTS: Mean age was 34.3 years (95% confidence interval: 33.6-35.0). The female-to-male ratio was 2.3:1. At least minimal depressive symptoms (BDI-II > 8) were present in = 256 (32.8%), 25-OH-VD deficiency (<20 ng/ml) in = 398 (51.0%), = 246 (31.5%) participants were smokers. Presence of current relapse [coefficient () = 1.48, = 0.016], more severe fatigue ( = 0.26, < 0.0001), lower 25-OH-VD ( = -0.03, = 0.034) and smoking ( = 0.35, = 0.008) were associated with higher BDI-II scores. Sex, age, disease course, EDSS, month of visit, EBNA1-IgG levels and brain volumes at baseline were not. CONCLUSION: Depressive symptoms need to be assessed in early MS. Patients during relapse seem especially vulnerable to depressive symptoms. Contributing factors such as fatigue, vitamin D deficiency and smoking, could specifically be targeted in future interventions and should be investigated in prospective studies.
Neurol Neurochir Pol. 2022
Ther Adv Neurol Disord. 2024-3-26
Mult Scler Relat Disord. 2019-10-1
Mult Scler Relat Disord. 2024-8
J Neural Transm (Vienna). 2024-8
Nutrients. 2023-5-23
J Neurol Neurosurg Psychiatry. 2023-2
Front Neurol. 2022-6-17
Brain Commun. 2022-6-13
Neurol Neuroimmunol Neuroinflamm. 2022-5